Anipryl®

 

Millions of older dogs are being slowly isolated from their families due to canine CDS. Anipryl® helps control the clinical signs of CDS and dramatically improve the lives of dogs suffering from CDS, helping to restore and renew the relationships between senior dogs and their families.

In select cases Anipryl® might be of value in dogs of any age to control the clinical signs of canine Cushing’s disease, also known as canine pituitary-dependent hyperadrenocorticism (PDH).


Indications

Anipryl® is a prescription medication, only for use in dogs, and is available only through licensed veterinarians. Anipryl® tablets are indicated for the control of clinical signs associated with canine CDSand control of clinical signs associated with uncomplicated canine PDH or Cushing’s.


Dosage and Administration1

Anipryl® tablets are available in strength of 2, 5, 10, 15, and 30 mg and come in packages of 30 tablets each for monthly dispensing.

We will start your dog on a mild dose initially. Anipryl® is given by mouth once a day, preferably in the morning. Dosage adjustments are made based on response and tolerance to the drug by your dog. Please monitor your dog closely for possible adverse reactions associated with any increase in dose. These adverse reactions include vomiting, diarrhea, anorexia (poor appetite) and excess salivation.

Every 6 months your dog will need a blood panel and examination prior to refilling your dog’s prescription.

 

Treatment success is largely due to following instructions carefully:

1. Give the medication when directed

2. Give the medication as often as directed

3. Give all the medicine prescribed

4. Report anything unusual to your veterinarian as soon as possible

 

A printable “Senior Dog Behavior History Form” is available to assist in monitoring signs of CDS while taking Anipryl®. [view PDF form].


Mechanism of Action2

 

Proposed modes of action:

Anipryl® enhances dopaminergic nerve cell function

Increases dopamine synthesis and release

Inhibits dopamine reuptake

Decreases dopamine catabolism by inhibiting MaOB

Potentates dopamine action

May decrease toxic free radical production while increasing their removal

 


Efficacy

Studies using Anipryl® for the treatment of CDS have shown that after 30 days, 80% of dogs showed improvement in overall cognitive response compared to pretreatment evaluation and improvements in individual clinical signs also were observed. after 60 days, 77% of dogs showed improvement in overall cognitive response compared to pretreatment evaluation. after 30 days of treatment, 76% of dogs showed improvement in disorientation, 72% showed improvement in interaction with family members, 60% exhibited improvement in activity or sleep-wake cycle, and 55% displayed improvement in housetraining.1

When using Anipryl® for the treatment of Cushing’s, many dogs have shown signs of improvement within 2 weeks, but others may require up to 2 months before improvement is seen. Response varies from dog to dog1.


Safety

Data collected from all dogs that received Anipryl® at any time during a 60-day trial were monitored for side effects. In this study, diarrhea (4.2%), anorexia (3.6%), and vomiting (3.4%) were the most frequently reported side effects attributed to anipryl® administration.2

In earlier placebo-control clinical studies, most of the adverse events seen in dogs treated with Anipryl® were also seen in placebo-treated dogs, although rates in placebo-treated dogs were lower. The most common adverse events were vomiting, diarrhea, or changes in behavior.2

In all studies, side effects were mild to moderate. Abnormal clinical signs also may be associated with underlying disease, advanced age, or the development of an unrelated concurrent disease. As with any medication, owners should report any unexpected changes in appetite or behavior to their veterinarian.2

Concurrent use of Anipryl® with ephedrine, phenylpropanolamine, other MAO inhibitors such as amitraz, meperidine, or other opioids, and tricyclic antidepressants, tetracyclic antidepressants, or selective serotonin reuptake inhibitors is not recommended. If a senior dog is receiving multiple medications, the dog should be monitored more closely. Anipryl® is contraindicated for patients with known hypersensitivity to this drug. The safety of Anipryl® in breeding, pregnant and lactating bitches, and breeding dogs has not been determined.2


Additional Reading:

1. Cognitive Dysfunction Syndrome and Other Geriatric Behavior Problems; CE Advisor a supplement to Veterinary Medicine, Feb 1999.

2. Controlling CDS with Anipryl®: Post approval Field Research Results from Private Hospitals in the US; Pfizer Animal Health Technical Bulletin, Dec 2000.

You will need the adobe acrobat Reader to view and print the bulletins and forms, which are in PDF format. If you already have Acrobat® Reader, you can immediately download and print the documents. If you need a copy of the Adobe® Acrobat® Reader®, click the icon below to download it free of charge from Adobe®.


References:

1. Adding New Science to the Practice of Medicine – Senior Dog Health, Canine Cognitive Dysfunction Syndrome and Anipryl® Senior Health Care Advisor Program, Pfizer Animal Health

2. Campbell, S; Controlling CDS with Anipryl®: Post Approval Field Research Results from Private Hospitals in the US; Pfizer Animal Health Technical Bulletin, Dec 2000.

Developed for Long Beach Animal Hospital, by Glenna M Gobar DVM, MPVM, MS, courtesy of Pfizer Animal Health; Sept 2001